M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator
© 2023 the author(s), published by De Gruyter, Berlin/Boston..
OBJECTIVES: Minimal residual disease status in multiple myeloma is an important prognostic biomarker. Recently, personalized blood-based targeted mass spectrometry (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to measure minimal residual disease. However, quantification of MS-MRD requires a unique calibrator for each patient. The use of patient-specific stable isotope labelled (SIL) peptides is relatively costly and time-consuming, thus hindering clinical implementation. Here, we introduce a simplification of MS-MRD by using an off-the-shelf calibrator.
METHODS: SILuMAB-based MS-MRD was performed by spiking a monoclonal stable isotope labeled IgG, SILuMAB-K1, in the patient serum. The abundance of both M-protein-specific peptides and SILuMAB-specific peptides were monitored by mass spectrometry. The relative ratio between M-protein peptides and SILuMAB peptides allowed for M-protein quantification. We assessed linearity, sensitivity and reproducibility of SILuMAB-based MS-MRD in longitudinally collected sera from the IFM-2009 clinical trial.
RESULTS: A linear dynamic range was achieved of over 5 log scales, allowing for M-protein quantification down to 0.001 g/L. The inter-assay CV of SILuMAB-based MS-MRD was on average 11 %. Excellent concordance between SIL- and SILuMAB-based MS-MRD was shown (R2>0.985). Additionally, signal intensity of spiked SILuMAB can be used for quality control purpose to assess system performance and incomplete SILuMAB digestion can be used as quality control for sample preparation.
CONCLUSIONS: Compared to SIL peptides, SILuMAB-based MS-MRD improves the reproducibility, turn-around-times and cost-efficacy of MS-MRD without diminishing its sensitivity and specificity. Furthermore, SILuMAB can be used as a MS-MRD quality control tool to monitor sample preparation efficacy and assay performance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 62(2024), 3 vom: 26. Jan., Seite 540-550 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wijnands, Charissa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clonotypic peptide |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 27.01.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2023-0781 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363164391 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363164391 | ||
| 003 | DE-627 | ||
| 005 | 20240127231844.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-0781 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1272.xml |
| 035 | |a (DE-627)NLM363164391 | ||
| 035 | |a (NLM)37823394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wijnands, Charissa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 27.01.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 the author(s), published by De Gruyter, Berlin/Boston. | ||
| 520 | |a OBJECTIVES: Minimal residual disease status in multiple myeloma is an important prognostic biomarker. Recently, personalized blood-based targeted mass spectrometry (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to measure minimal residual disease. However, quantification of MS-MRD requires a unique calibrator for each patient. The use of patient-specific stable isotope labelled (SIL) peptides is relatively costly and time-consuming, thus hindering clinical implementation. Here, we introduce a simplification of MS-MRD by using an off-the-shelf calibrator | ||
| 520 | |a METHODS: SILuMAB-based MS-MRD was performed by spiking a monoclonal stable isotope labeled IgG, SILuMAB-K1, in the patient serum. The abundance of both M-protein-specific peptides and SILuMAB-specific peptides were monitored by mass spectrometry. The relative ratio between M-protein peptides and SILuMAB peptides allowed for M-protein quantification. We assessed linearity, sensitivity and reproducibility of SILuMAB-based MS-MRD in longitudinally collected sera from the IFM-2009 clinical trial | ||
| 520 | |a RESULTS: A linear dynamic range was achieved of over 5 log scales, allowing for M-protein quantification down to 0.001 g/L. The inter-assay CV of SILuMAB-based MS-MRD was on average 11 %. Excellent concordance between SIL- and SILuMAB-based MS-MRD was shown (R2>0.985). Additionally, signal intensity of spiked SILuMAB can be used for quality control purpose to assess system performance and incomplete SILuMAB digestion can be used as quality control for sample preparation | ||
| 520 | |a CONCLUSIONS: Compared to SIL peptides, SILuMAB-based MS-MRD improves the reproducibility, turn-around-times and cost-efficacy of MS-MRD without diminishing its sensitivity and specificity. Furthermore, SILuMAB can be used as a MS-MRD quality control tool to monitor sample preparation efficacy and assay performance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a M-protein | |
| 650 | 4 | |a clonotypic peptide | |
| 650 | 4 | |a minimal residual disease | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a targeted mass spectrometry | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Isotopes |2 NLM | |
| 700 | 1 | |a Langerhorst, Pieter |e verfasserin |4 aut | |
| 700 | 1 | |a Noori, Somayya |e verfasserin |4 aut | |
| 700 | 1 | |a Keizer-Garritsen, Jenneke |e verfasserin |4 aut | |
| 700 | 1 | |a Wessels, Hans J C T |e verfasserin |4 aut | |
| 700 | 1 | |a Gloerich, Jolein |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifay, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Caillon, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Luider, Theo M |e verfasserin |4 aut | |
| 700 | 1 | |a van Gool, Alain J |e verfasserin |4 aut | |
| 700 | 1 | |a Dejoie, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a VanDuijn, Martijn M |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Joannes F M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 62(2024), 3 vom: 26. Jan., Seite 540-550 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2024 |g number:3 |g day:26 |g month:01 |g pages:540-550 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2023-0781 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2024 |e 3 |b 26 |c 01 |h 540-550 | ||